Evaluating the immunogenic potential of BAX protein isoforms as therapeutic targets in oncology: brief report

Abstract

Through a methodical approach that combines bioinformatics and immunological analysis, detailed genetic sequencing and structural analysis of seven BAX isoforms were conducted. Using databases such as NCBI and Uniprot, and algorithms for sequence alignment and structural predictions, promising features in specific isoforms were identified. Tools like BCPREDS and the Immune Epitope Database helped evaluate the immunogenic potential by mapping epitopes. The results highlighted that isoforms such as BAX-alpha and BAX-gamma have high immunogenic capacities, making them candidates for the development of targeted vaccines or as direct therapeutic agents. Structural analyses suggested that some isoforms have the capability to integrate into cell membranes and alter signaling pathways, inducing apoptosis selectively in cancer cells. In summary, this study underscores the importance of BAX isoforms in the evolution of cancer therapy, offering more specific treatment approaches with lower toxicity. These findings encourage a move towards precision medicine in oncology, personalizing treatments based on molecular and genetic profiles to optimize therapeutic efficacy and reduce adverse effects, promising to improve outcomes for patients.